Fekete Klára Edit, Héja Máté, Márton Sándor, Tóth Judit, Harman Aletta, Horváth László, Fekete István
Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Institute of Political Science and Sociology, Faculty of Arts, University of Debrecen, Debrecen, Hungary.
Front Neurol. 2023 Feb 1;14:1080046. doi: 10.3389/fneur.2023.1080046. eCollection 2023.
Acute ischemic stroke (AIS) is a potentially devastating disease with high disability and mortality. Recombinant tissue plasminogen activator (rt-PA) is an effective treatment with a 2-8% possible risk for symptomatic intracranial hemorrhage (sICH). Our aim was to investigate the risk factors and long-term clinical outcomes of ICH in patients after rt-PA treatment.
Consecutive patients with AIS, thrombolysed at the Department of Neurology, University of Debrecen, between 1 January 2004 and 31 August 2016 were enrolled prospectively. Risk factors, stroke severity based on the National Institute of Health Stroke Scale (NIHSS), functional outcome using the modified Rankin scale, and mortality at 1 year were compared in patients with and without ICH following rt-PA treatment. We evaluated clinical characteristics and prognosis by hemorrhage type based on the Heidelberg Bleeding Classification. Descriptive statistics, the chi-square test, the Mann-Whitney -test, ANOVA, the Kruskal-Wallis test, a survival analysis, and logistic regression were performed as appropriate.
Out of 1,252 patients with thrombolysis, ICH developed in 138 patients, with 37 (2.95%) being symptomatic. Mean ages in the ICH and non-ICH groups differed significantly ( = 0.041). On admission, the 24-h NIHSS after thrombolysis was higher in patients with ICH ( < 0.0001). Large vessel occlusion was more prevalent in patients with ICH ( = 0.0095). The ICH risk was lower after intravenous thrombolysis than intra-arterial or combined thrombolysis ( < 0.0001). Both at 3 months and 1 year, the outcome was worse in patients with ICH compared to patients without ICH group ( < 0.0001). Mortality and poor outcome were more prevalent in all hemorrhage types with a tendency for massive bleeding associated with unfavorable prognosis. At 3 months with the logistic regression model, the worse outcome was detected in patients with ICH after thrombolysis, at 1 year in patients with ICH after thrombolysis and smoking.
Older age, higher NIHSS, large vessel occlusion, and intra-arterial thrombolysis may correlate with ICH. The unfavorable outcome is more common in patients with ICH. Precise scoring of post-thrombolysis bleeding might be a useful tool in the evaluation of the patient's prognosis. Our findings may help to identify predictors and estimate the prognosis of ICH in patients with AIS treated with rt-PA.
急性缺血性卒中(AIS)是一种具有高致残率和死亡率的潜在毁灭性疾病。重组组织型纤溶酶原激活剂(rt-PA)是一种有效的治疗方法,但有2%-8%的症状性颅内出血(sICH)风险。我们的目的是研究rt-PA治疗后患者发生颅内出血的危险因素和长期临床结局。
前瞻性纳入2004年1月1日至2016年8月31日在德布勒森大学神经病学系接受溶栓治疗的连续性AIS患者。比较rt-PA治疗后发生颅内出血和未发生颅内出血患者的危险因素、基于美国国立卫生研究院卒中量表(NIHSS)的卒中严重程度、改良Rankin量表评估的功能结局以及1年死亡率。我们根据海德堡出血分类法按出血类型评估临床特征和预后。酌情进行描述性统计、卡方检验、Mann-Whitney检验、方差分析、Kruskal-Wallis检验、生存分析和逻辑回归。
在1252例接受溶栓治疗的患者中,138例发生颅内出血,其中37例(2.95%)为症状性颅内出血。颅内出血组和非颅内出血组的平均年龄差异有统计学意义(P = 0.041)。入院时,颅内出血患者溶栓后24小时NIHSS评分更高(P < 0.0001)。颅内出血患者大血管闭塞更为常见(P = 0.0095)。静脉溶栓后颅内出血风险低于动脉内溶栓或联合溶栓(P < 0.0001)。在3个月和1年时,颅内出血患者的结局比未发生颅内出血的患者更差(P < 0.0001)。所有出血类型中死亡率和不良结局更为常见,大量出血与不良预后相关。在3个月时,逻辑回归模型显示溶栓后颅内出血患者结局较差,在1年时,溶栓后颅内出血且吸烟的患者结局较差。
年龄较大、NIHSS评分较高、大血管闭塞和动脉内溶栓可能与颅内出血相关。颅内出血患者不良结局更为常见。溶栓后出血的精确评分可能是评估患者预后的有用工具。我们的研究结果可能有助于识别急性缺血性卒中接受rt-PA治疗患者颅内出血的预测因素并估计其预后。